Rosetta, Precision Therapeutics Amend Co-marketing Deal Again | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Thursday it and Precision Therapeutics have amended their co-marketing deal entered into in July 2012 and revised in October.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.